- Home
- ROIV vs EHC Comparison
ROIV vs EHC Comparison
Compare ROIV & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | EHC |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 12.4B |
| IPO Year | N/A | 1986 |
Fundamental Metrics
Financial Performance| Metric | ROIV | EHC |
|---|---|---|
| Price | $21.33 | $107.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $24.31 | ★ $141.88 |
| AVG Volume (30 Days) | ★ 8.3M | 1.1M |
| Earning Date | 02-09-2026 | 02-05-2026 |
| Dividend Yield | N/A | ★ 0.71% |
| EPS Growth | N/A | ★ 27.89 |
| EPS | N/A | ★ 5.29 |
| Revenue | $20,329,000.00 | ★ $5,795,600,000.00 |
| Revenue This Year | N/A | $11.54 |
| Revenue Next Year | $741.42 | $8.76 |
| P/E Ratio | ★ N/A | $20.06 |
| Revenue Growth | N/A | ★ 11.13 |
| 52 Week Low | $8.73 | $87.85 |
| 52 Week High | $23.47 | $127.99 |
Technical Indicators
Market Signals| Indicator | ROIV | EHC |
|---|---|---|
| Relative Strength Index (RSI) | 48.66 | 42.28 |
| Support Level | $21.36 | $103.58 |
| Resistance Level | $22.21 | $108.56 |
| Average True Range (ATR) | 0.73 | 1.86 |
| MACD | -0.17 | 0.30 |
| Stochastic Oscillator | 19.30 | 77.31 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About EHC Encompass Health Corporation
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. These hospitals are concentrated in the eastern half of the United States and Texas.